How Do Xofluza and Tamiflu Work Against Flu?
Xofluza (baloxavir marboxil) is a single-dose antiviral that blocks influenza A and B virus replication by inhibiting the endonuclease enzyme needed for viral RNA capping. Tamiflu (oseltamivir) is taken twice daily for five days and inhibits neuraminidase, an enzyme viruses use to exit host cells. Both shorten flu duration but target different viral steps.[1]
What Clinical Trials Show on Effectiveness?
In phase 3 trials for uncomplicated flu in adolescents and adults:
- Xofluza reduced time to symptom alleviation by 2.5 days less than placebo (median 54 vs 80 hours).
- Tamiflu reduced it by about 1 day less than placebo (median 72 vs 80 hours).
Direct comparison in a Japanese trial (n=1,232) found Xofluza superior: median alleviation time of 54 hours vs 73 hours for Tamiflu (p<0.0001). Xofluza also cut viral titer faster.[2][3]
In children (5-11 years), Xofluza showed similar one-day faster recovery than placebo; Tamiflu data aligns with adult reductions.[4]
| Endpoint | Xofluza | Tamiflu |
|----------|---------|---------|
| Median time to relief (adults) | 54 hours | 73-80 hours |
| Dosing | Single dose | 5 days, twice daily |
| Trial superiority | Beat placebo and Tamiflu head-to-head | Beat placebo |
Does Xofluza Work Better in High-Risk or Severe Cases?
Xofluza matches Tamiflu in hospitalized patients but lacks large head-to-head data there. Both reduce complications like pneumonia by 50-60% vs no treatment, per meta-analyses. Xofluza's single dose improves adherence, potentially boosting real-world effectiveness.[5][6]
Resistance and When One Might Fail
Xofluza resistance emerges in 2-3% of treated cases (higher in kids under 5), similar to Tamiflu's 1-4% rate. No cross-resistance. Guidelines recommend Xofluza first-line for uncomplicated flu due to efficacy and convenience; Tamiflu for hospitalized or oseltamivir-susceptible strains.[7]
Cost and Access Comparison
Xofluza costs $150-180 per dose (U.S. cash price); Tamiflu generic is $20-50 for a course. Insurance often covers both, but Xofluza's single dose cuts copays. Patents: Xofluza exclusivity runs to 2031 (U.S. Patent 9,249,151 expires 2030); Tamiflu generics available since 2016.[8][9]
Sources
[1] FDA Label: Xofluza (2018) - fda.gov
[2] NEJM: Baloxavir vs Oseltamivir (2019) - nejm.org
[3] Lancet Infect Dis: CAPSTONE-2 Trial (2020) - thelancet.com
[4] FDA Label: Xofluza Pediatric (2020)
[5] MMWR CDC: Antivirals in High-Risk Flu (2023) - cdc.gov
[6] Cochrane Review: Neuraminidase Inhibitors (2014, updated)
[7] IDSA Guidelines: Influenza (2018) - idsociety.org
[8] GoodRx Pricing Data (2024)
[9] DrugPatentWatch: Xofluza Patents - drugpatentwatch.com